European Multi-Centre Post-Market Registry on Thoracic Endovascular Arch Repair Using Castor™ and Cratos™ (CEDAR)
European Multi-Centre Castor™ and Cratos™ Branched Endovascular Arch Repair Registry
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Maggie Shen, MD MSc
- Telefonnummer: 00441235750800
- E-mail: maggie.shen@endovastec-lm.com
Undersøgelse Kontakt Backup
- Navn: Anne Woodman
- Telefonnummer: 00441235750800
- E-mail: anne.woodman@endovastec-lm.com
Studiesteder
-
-
-
Sion, Schweiz, 1951
- Rekruttering
- Hopital de Sion
-
Kontakt:
- Daniel Danzer
- Telefonnummer: 0041276034124
- E-mail: daniel.danzer@hopitalvs.ch
-
Ledende efterforsker:
- Daniel Danzer
-
Zurich, Schweiz, CH-8091
- Rekruttering
- Universitätsspital Zürich (USZ)
-
Kontakt:
- Susanne Menz
- Telefonnummer: 0041432530243
- E-mail: Susanne.Menz@usz.ch
-
Ledende efterforsker:
- Alexander Zimmermann, Prof. Dr. med.
-
Underforsker:
- Benedikt Reutersberg,, PD Dr. med.
-
-
-
-
-
Hamburg, Tyskland, 20099
- Rekruttering
- ASKLEPIOS Kliniken St. Georg
-
Kontakt:
- Prof. Dr. med.
- Telefonnummer: 2492 004940181885
- E-mail: t.koeppel@asklepios.com
-
Ledende efterforsker:
- Thomas A Koeppel, Prof. Dr. med.
-
Underforsker:
- Hans Christian Voigt, Dr. med. univ.
-
Münster, Tyskland, 48149
- Rekruttering
- Universitätsklinikum Münster (UKM)
-
Kontakt:
- Jana Ebing
- Telefonnummer: 00492518351717
- E-mail: vital@ukmuenster.de
-
Ledende efterforsker:
- Alexander Oberhuber, Dr. med. univ.
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Implantation of a Castor™ or Cratos™ single branch endoprothesis with incorporation of the left subclavian artery
- Age >18 years
Exclusion Criteria:
- Patients allergic to the materials of the device;
- Patients with severe or potentially systemic infections that increase the chance of graft infection;
- Minors and pregnant women;
- Branch for other supra-aortic vessels than the LSA
- Rejection of participation.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Cohort 1: patients treated with Castor™
Arch involving aortic pathologies treated with the Castor™ stent graft system.
|
Treatment of subjects diagnosed with thoracic aortic pathologies using the Castor™ Branched Aortic Stent-Graft and Delivery System.
Follow up as per institutional standard of care.
|
|
Cohort 2: patients treated with Cratos™
Arch involving aortic pathologies treated with the Cratos™ stent graft system.
|
Treatment of subjects diagnosed with thoracic aortic pathologies using the Cratos™ Branched Aortic Stent-Graft and Delivery System.
Follow up as per institutional standard of care.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
30-day all-cause mortality
Tidsramme: 30 days
|
A measure of the total number of patients participating in the CEDAR study who die from any cause within 30 days of the implantation of the branched aortic stent graft - Castor™ or Cratos™.
|
30 days
|
|
Technical success rate
Tidsramme: 24 hours
|
Technical Success is defined as successful access and deployment of the endograft, including implantation of the branch into the target vessel, with patency of the branch and no evidence of type I or type III endoleak on completion angiography or cone-beam computed tomography.
Additional intra-operative measures to achieve this, such as ballooning or branch extension with additional stent grafts, are also considered as primary technical success.
|
24 hours
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical success rate at 30 days, 6 months and at 1 - 5 years
Tidsramme: at 30 days, 6 months and at 1 - 5 years
|
This is defined as Technical Success plus the absence of aortic related death, aortic rupture, graft infection, sac expansion > 5mm, graft migration >10mm, persistent endoleaks type I and III requiring re-intervention, conversion to open surgery, permanent paraplegia, disabling stroke or permanent dialysis.
|
at 30 days, 6 months and at 1 - 5 years
|
|
Rate of Endoleak
Tidsramme: at 30 days, 6 months, and at 1 - 5 years
|
at 30 days, 6 months, and at 1 - 5 years
|
|
|
Branch occlusion rate
Tidsramme: at 30 days, 6 months, and 1-5 year
|
at 30 days, 6 months, and 1-5 year
|
|
|
Rate of perioperative retrograde type A aortic dissections
Tidsramme: 30 days, 6 months, and at 1 - 5 years
|
30 days, 6 months, and at 1 - 5 years
|
|
|
Rate of reintervention
Tidsramme: at 30 days, 6 months, and at 1-5 years
|
at 30 days, 6 months, and at 1-5 years
|
|
|
Combined endpoint major adverse events
Tidsramme: at 30-days, 6 months and 1 year
|
all-cause mortality, myocardial infarction, respiratory failure with postoperative prolonged mechanical ventilation > 24h, renal function declining in a GFR > 50% reduction to perioperative, bowel ischemia requiring surgical resection, major stroke and permanent paraplegia.
|
at 30-days, 6 months and 1 year
|
|
Incidence rate of spinal cord ischemia for the duration of the study
Tidsramme: at 30 days, 6 months, and at 1 - 5 years
|
at 30 days, 6 months, and at 1 - 5 years
|
|
|
Stroke rate
Tidsramme: at 30 days, 6 months, and at 1 - 5 years
|
at 30 days, 6 months, and at 1 - 5 years
|
|
|
All-cause mortality
Tidsramme: at 30 days, 6 months, and at 1 - 5 years
|
at 30 days, 6 months, and at 1 - 5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Jing Wang, Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Dissektion, Blodkar
- Akut aortasyndrom
- Karsygdomme
- Hjerte-kar-sygdomme
- Patologiske processer
- Blødning
- Åreforkalkning
- Arterielle okklusive sygdomme
- Aorta sygdomme
- Aneurisme
- Aortadissektion
- Patologiske tilstande, tegn og symptomer
- Hæmatom
- Penetrerende aterosklerotisk ulcus
- Dissektion, Thoracic Aorta
- Aorta intramuralt hæmatom
- Aortaaneurisme
- Aortaaneurisme, thorax
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- PMCF-2025-01
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .